RASopathies represent a group of diseases that are increasingly being recognized and studied. Consequently, efforts have been made to improve the quality of life of these patients, in particular the treatment with GH because of their short stature. Most papers dealing with the GH treatment of RASopathies concern the Noonan syndrome and the influence of PTPN11 mutations. However, little is known regarding GH treatment and final height in other RASopathies, such as Noonan-like syndrome with loose anagen hair (NS-LAH).

Additionally, nothing is known about the potential cancerogenic risk of GH treatment and whether GH treatment might negatively influence hypertrophic cardiomyopathy (HCM), often seen in these patients.

Another interesting point is the pubertal delay frequently observed of these children. It has not been investigated whether they would benefit from a substitutive treatment and whether this treatment would influence the effect of GH treatment on final height.

A standard EDITORIAL TRACKING SYSTEM is utilized for manuscript submission, review, editorial processing and tracking which can be securely accessed by the authors, reviewers and editors for monitoring and tracking the article processing. Manuscripts can be uploaded online at Editorial Tracking System (https://www.longdom.org/submissions/hair-therapy-transplantation.html) or forwarded to the Editorial Office at hairtherapy@emedscholar.com

Media Contact:               

Sandra Jones

Journal Manager

Hair Therapy and Transplantation

Email: hairtherapy@emedscholar.com